访谈优先——研究开始前先提出澄清问题

Before starting the deep research run, I need to clarify the scope (Step 1 of the workflow). Please answer the following — one round, then I'll proceed: 1. **Safety outcomes**: Which toxicities matter most — CRS/ICANS only, on-target/off-tumor toxicity, or the full safety spectrum (including neurotoxicity, hematologic toxicity, insertional oncogenesis concerns)? 2. **Tumor scope**: Pan-solid-tumor overview, or specific indications (e.g., glioblastoma, pancreatic, ovarian, lung)? … 3. **Time window**: Last 5 years, or all available evidence? 4. **Evidence scope**: Clinical trials only, or also include reviews/meta-analyses, case reports, and regulatory (FDA) documents? 5. **Output format**: Default is a full report with numbered citations as Markdown + rendered HTML under `reports/` — is that fine, or Markdown-only (`no-html`)? I'll wait for your reply before decomposing the topic and launching the research. (Opening + all five questions verbatim from the session transcript; ellipsis only shortens the question list inside Q2.)